NASDAQ: CRVO · Life Sciences · 8 alerts · CIK 1053691
Share price
$1.67Close, Nov 16
Market cap
$25.3M
Shares outstanding
15.13MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All CervoMed Inc. filings on SEC EDGAR ↗
CervoMed presented 24-week interim biomarker data from its Phase 2a trial of neflamapimod in patients with nonfluent variant primary progressive aphasia (nfvPPA). The data showed an exposure-dependent reduction in neurofilament light chain (NfL), a key biomarker of neuronal damage, in patients with higher plasma drug levels. Full 24-week biomarker and clinical data from the study are expected in the first quarter of 2027.
CervoMed reported Q3 2026 financial results and provided updates on its neflamapimod clinical program, including the removal of FDA drug exposure limits and the receipt of an Innovation Passport designation in the UK for dementia with Lewy bodies. The company ended the quarter with $31.1 million in cash and cash equivalents, which is expected to fund operations into late 2025.
Term
Q3 2026
“The Company believes that the neflamapimod clinical development program has been significantly de-risked through the presentation and publication of compelling, supportive datasets throughout this year and the ability to advance the 100mg BID dosing regimen, strengthening its position as a potential therapeutic for dementia with Lewy bodies and other devastating neurodegenerative disorders.”
John Alam, MD, Chief Executive Officer of CervoMed
“As we look ahead to the remainder of the year and into 2027, we believe neflamapimod is well-positioned to succeed in the clinic, drive stockholder value, and ultimately, if approved, bring a transformative therapy to a market with massive, unmet medical needs.”
John Alam, MD, Chief Executive Officer of CervoMed
CervoMed Inc. reported a net loss of $20.4 million for the nine months ended September 30, 2026, as it continues clinical development of neflamapimod. The company's cash position of $19.6 million is insufficient to fund operations for the next twelve months, leading to a 'going concern' qualification.
CervoMed announced the publication of peer-reviewed results from its Phase 2b RewinD-LB clinical trial of neflamapimod in dementia with Lewy bodies (DLB). While the trial did not meet its primary endpoint in the full population, data showed a statistically significant increase in right basal forebrain volume and greater clinical benefit in patients without Alzheimer’s disease co-pathology.
CervoMed Inc. announced that it has updated its corporate presentation containing information about its business, clinical studies, and development plans. The presentation is being made available on the company's website and will be used by management in upcoming meetings and conferences with investors and analysts.
CervoMed announced positive initial 12-week biomarker data from its Phase 2a clinical trial of neflamapimod in patients with nonfluent variant primary progressive aphasia (nfvPPA). The data showed a mean reduction in plasma neurofilament light chain (NfL) levels, a key marker of neurodegeneration, which contrasts with the increases typically seen in the natural history of the disease.
CervoMed Inc. has updated its corporate investor presentation, which is being made available on the company's website. The presentation covers the company's business, clinical studies, development plans, and financial position, and will be used by management in upcoming meetings with investors and analysts.
CervoMed announced pharmacokinetic and regulatory updates for its lead drug candidate, neflamapimod, including a new 50 mg oral tablet formulation and the FDA's removal of a previous drug exposure limit. These developments allow the company to advance a 100 mg twice-daily dosing regimen in future clinical trials, which is expected to achieve higher drug concentrations and improve patient convenience compared to prior three-times-daily dosing.